Though SE was the most effective therapy for Bowen disease, the risk for recurrence with 5-FU and MAL-PDT was negligible.

The FDA updated its safety labeling for capecitabine and 5-FU to reflect that patients with certain genetic variants risk ...

A new case report was published in Volume 12 of Oncoscience on December 23, 2025, titled "Silent toxicity: A rare case of ...

Complete DPD deficiency markedly impairs 5-FU catabolism, increasing risk of early severe diarrhea, mucositis, neutropenia, ...

The FDA has updated the safety labeling for the chemotherapeutic agents capecitabine (Xeloda) and fluorouracil (5-FU) to ...

A new case report was published in Volume 12 of Oncoscience on December 23, 2025, titled “Silent toxicity: A rare case of ...

Surgical treatment of colorectal liver metastasis after neoadjuvant chemotherapy. Background: 5-fluorouracil (5-FU) is a agent of chemotherapy that has been associated with cardiotoxicity infrequently ...

Prevalence and prognostic significance of myeloid-derived suppressor cells and regulatory T cells in pancreatic and esophagogastric cancer. Background: Thymidylate synthase (TYMS) is the target of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. KOLOA, Hawaii — The use of topical 5-fluorouracil ...

One technology, the My5‑FU assay, was identified during scoping as being relevant to this assessment. The My5‑FU assay can be used to guide pharmacokinetic dose adjustment and to monitor the levels of ...